skip to main content
Close Icon We use cookies to improve your website experience.  To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy.  By continuing to use the website, you consent to our use of cookies.
Global Search Configuration

Refine Results

Clear All

Specialism

Show More

Resources

Show More

Show More

Products

Show More

Show More

100+ Total results for product and free and sample content found

Pharma 360

Global Oncology Opportunities & Trends 2025: Key Markets, Indications and Product

13 May 2022

Pharma Intelligence

Join Informa Pharma Intelligence for the “Global Oncology Opportunities” webinar! 

Chemist + Druggist Data

New pip codes for Northern Ireland and Great Britain

11 Mar 2022

New pip codes for Northern Ireland and Great Britain

We are pleased to announce that from mid-February 2022, C+D Data will provide the UK supply chain with additional product listings and associated PIP-codes for Northern Ireland (NI) and Great Britain (GB.)  This solution will allow you to reach the entire UK market quickly and facilitate the ordering and distribution of medicines without disruption to you, and your wholesalers – while ensuring the data’s accuracy, visibility, and long-term management. 

Pink Sheet

Accelerated Approval Makes Big Splash In 2021 Novel Agents, Despite Crackdown On ‘Dangling’ Cancer Claims

By Bridget Silverman 19 Jan 2022

PS2201_PP_bigsplash_1200

US FDA’s accelerated approvals hit a contemporary high in 2021, accounting for one-third of novel US approvals, but the big story was the agency’s crackdown on delinquent confirmatory trials for oncology AA indications.

Pink Sheet

Care Needed With Plain Language Summaries Of EU Study Results

By Vibha Sharma 18 Jan 2022

PS2008_Simple_392723311_1200

The EU will make it mandatory for clinical trial sponsors to prepare layperson summaries of their study results. Industry practices around content presentation, translation and dissemination of these documents will be keenly watched.

Generics Bulletin

Multiple Molecules See UK Prices More Than Double In December

By David Wallace 18 Jan 2022

GB2109_Price_watch_UK_2_2AP631W_1200

WaveData’s compilation of the fastest-rising UK generics prices in December showed several products across multiple presentations more than doubling their average trade prices to independent pharmacists.

Scrip

Coronavirus Update: Korea Approval For Nuvaxovid, Japan Filing For Paxlovid

By Scrip Team 18 Jan 2022

IV062021_SouthKoreaBusinessGrowth

More progress for vaccines and oral antivirals in Asia as South Korea issues an approval for Novavax's vaccine, Pfizer files for Japanese approval of Paxlovid, and SK bio progresses late-stage trials of its recombinant vaccine. 

Scrip

Deal Watch: How Did J.P. Morgan Deal-Making Compare To Prior Years?

By Joseph Haas 17 Jan 2022

Deal_Watch_592000391_1200_675_1200

Licensing deals and partnerships carried the day during another hectic J.P. Morgan Healthcare Conference. Pfizer racked up its third deal of the week in a cancer collaboration with Dren Bio.

Scrip

Quick Listen: Scrip's Five Must-Know Things

By Ian Haydock 17 Jan 2022

SC2008_FiveMustKnowThings_1200_Final

In this week's podcast edition of Five Must-Know Things: easy alliances rather than big deals the focus at JP Morgan; multiple company roundups from JPM; and Lilly braces for impact of US CMS decision on Aduhelm.

Next steps

Getting a demo tailored to your needs is the best way to see how our solutions will help you gain an advantage.

Request live demo now:

Our team is ready to hear from you for a particular request or area of interest. Please do not hesitate to reach out and discuss.

Contact us for product technical and account support.

  • US Toll-Free   : +1 888 670 8900 
  • US Toll             : +1 212-600-3520
  • UK & Europe : +44 (0) 208 052 0700

Have an immediate and specific information need?

Browse and buy from 1000s of analysis and research reports now: